Outcome of Board Meeting held on May 12, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals reported FY25 audited results on May 12, 2025 with unmodified auditor opinion. Standalone revenue rose to Rs. 30,413 lakhs (up ~18% from Rs. 25,798 lakhs) and net profit grew to Rs. 2,645 lakhs (up ~17% from Rs. 2,259 lakhs), with EPS at Rs. 40.36. The board recommended a final dividend of Rs. 1 per share (10% on face value of Rs. 10). On a consolidated basis, revenue jumped ~30% to Rs. 34,038 lakhs but the company swung to a net loss of Rs. 4,368 lakhs versus a Rs. 1,051 lakh profit last year, with EBITDA margin sharply compressing from 12.16% to 4.21% and negative operating cashflow of Rs. 2,725 lakhs. During the year, the company acquired 100% stake in Varenyam Healthcare and 40% in Varenyam Biolifesciences via share swaps, and acquired additional stake in subsidiary Innoxel Lifesciences for Rs. 6,481 lakhs. New Secretarial, Cost, and Internal Auditors were also appointed for FY26.
Shareholders will receive a Rs. 1 per share final dividend if approved at the AGM. While standalone numbers look steady, the consolidated loss and sharp EBITDA margin compression highlight rising costs and integration risk from newly acquired subsidiaries, which could pressure the stock in the near term despite the dividend cushion.